Linezolid-Associated Neuropathy in Patients with MDR/XDR Tuberculosis in Shenzhen, China

References

• World Health Organization. Global Tuberculosis Report 2021. Geneva, Switzerland: World Health Organization; 2021.
   Google Scholar
• Singh B, Cocker D, Ryan H, Sloan DJ. Linezolid for drug-resistant pulmonary tuberculosis. Cochrane Database Syst Rev. 2019;3:CD012836. doi:10.1002/14651858.CD012836.pub2
   PubMed Web of Science ®Google Scholar
• World Health Organization. Rapid communication: key changes to treatment of multidrug- and rifampicin-resistant tuberculosis (MDR/RR-TB). Available from: http://www.who.int/tb/publications/2018/rapid_communications_MDR. Accessed May 13, 2022.
   Google Scholar
• Agyeman AA, Ofori-Asenso R. Efficacy and safety profile of linezolid in the treatment of multidrug-resistant (MDR) and extensively drug-resistant (XDR) tuberculosis: a systematic review and meta-analysis. Ann Clin Microbiol Antimicrob. 2016;15(1):41. doi:10.1186/s12941-016-0156-y
   PubMed Web of Science ®Google Scholar
• Conradie F, Diacon AH, Ngubane N, et al. Treatment of highly drug-resistant pulmonary tuberculosis. N Engl J Med. 2020;382(10):893–902. doi:10.1056/NEJMoa1901814
   PubMed Web of Science ®Google Scholar
• Tang S, Yao L, Hao X, et al. Efficacy, safety and tolerability of linezolid for the treatment of XDR-TB: a study in China. Eur Respir J. 2015;45(1):161–170. doi:10.1183/09031936.00035114
   PubMed Web of Science ®Google Scholar
• Borisov S, Danila E, Maryandyshev A, et al. Surveillance of adverse events in the treatment of drug-resistant tuberculosis: first global report. Eur Respir J. 2019;54:1901522. doi:10.1183/13993003.01522-2019
   PubMed Web of Science ®Google Scholar
• Koh WJ, Kwon OJ, Gwak H, et al. Daily 300 mg dose of linezolid for the treatment of intractable multidrug-resistant and extensively drug-resistant tuberculosis. J Antimicrob Chemother. 2009;64(2):388–391. doi:10.1093/jac/dkp171
   Web of Science ®Google Scholar
• Koh WJ, Kang YR, Jeon K, et al. Daily 300 mg dose of linezolid for multidrug-resistant and extensively drug-resistant tuberculosis: updated analysis of 51 patients. J Antimicrob Chemother. 2012;67(6):1503–1507. doi:10.1093/jac/dks078
   PubMed Web of Science ®Google Scholar
• Song T, Lee M, Jeon HS, et al. Linezolid trough concentrations correlate with mitochondrial toxicity-related adverse events in the treatment of chronic extensively drug-resistant tuberculosis. EBioMedicine. 2015;2(11):1627–1633. doi:10.1016/j.ebiom.2015.09.051
   PubMed Web of Science ®Google Scholar
• Lee M, Lee J, Carroll MW, et al. Linezolid for treatment of chronic extensively drug-resistant tuberculosis. N Engl J Med. 2012;367(16):1508–1518. doi:10.1056/NEJMoa1201964
   PubMed Web of Science ®Google Scholar
• Jaspard M, Butel N, El helali N, et al. Linezolid-associated neurologic adverse events in patients with multidrug-resistant tuberculosis, France. Emerg Infect Dis. 2020;26(8):1792–1800. doi:10.3201/eid2608.191499
   Web of Science ®Google Scholar
• Cherry CL, Wesselingh SL, Lal L, McArthur JC. Evaluation of a clinical screening tool for HIV-associated sensory neuropathies. Neurology. 2005;65(11):1778–1781. doi:10.1212/01.wnl.0000187119.33075.41
   PubMed Web of Science ®Google Scholar
• Feldman EL, Stevens MJ, Thomas PK, Brown MB, Canal N, Greene DA. A practical two-step quantitative clinical and electrophysiological assessment for the diagnosis and staging of diabetic neuropathy. Diabetes Care. 1994;17(11):1281–1289. doi:10.2337/diacare.17.11.1281
   PubMed Web of Science ®Google Scholar
• Mohammad MT, Muhaidat J, Momani MS, et al. Translation and psychometric properties of the Arabic version of Michigan neuropathy screening instrument in type 2 diabetes. J Diabetes Res. 2019;2019:2673105. doi:10.1155/2019/2673105
   PubMed Web of Science ®Google Scholar
• Herman WH, Pop-Busui R, Braffett BH, et al. Use of the Michigan Neuropathy Screening Instrument as a measure of distal symmetrical peripheral neuropathy in Type 1 diabetes: results from the Diabetes Control and Complications Trial/Epidemiology of Diabetes Interventions and Complications. Diabet Med. 2012;29(7):937–944. doi:10.1111/j.1464-5491.2012.03644.x
   PubMed Web of Science ®Google Scholar
• Kishor K, Dhasmana N, Kamble SS, Sahu RK. Linezolid induced adverse drug reactions - an update. Curr Drug Metab. 2015;16(7):553–559. doi:10.2174/1389200216666151001121004
   PubMed Web of Science ®Google Scholar
• Bolhuis MS, Akkerman OW, Sturkenboom MGG, et al. Linezolid-based regimens for multidrug-resistant tuberculosis (TB): a systematic review to establish or revise the current recommended dose for TB treatment. Clin Infect Dis. 2018;67(suppl_3):S327–S335. doi:10.1093/cid/ciy625
   Web of Science ®Google Scholar
• Dempsey SP, Sickman A, Slagle WS. Case report: linezolid optic neuropathy and proposed evidenced-based screening recommendation. Optom Vis Sci. 2018;95(5):468–474. doi:10.1097/OPX.0000000000001216
   Web of Science ®Google Scholar
• Morata L, De la Calle C, Gómez-Cerquera JM, et al. Risk factors associated with high linezolid trough plasma concentrations. Expert Opin Pharmacother. 2016;17(9):1183–1187. doi:10.1080/14656566.2016.1182154
   PubMed Web of Science ®Google Scholar
• Bolhuis MS, Tiberi S, Sotgiu G, et al. Linezolid tolerability in multidrug-resistant tuberculosis: a retrospective study. Eur Respir J. 2015;46(4):1205–1207. doi:10.1183/13993003.00606-2015
   PubMed Web of Science ®Google Scholar
• Abou Hassan OK, Karnib M, El-Khoury R, Nemer G, Ahdab-Barmada M, BouKhalil P. Linezolid toxicity and mitochondrial susceptibility: a novel neurological complication in a Lebanese patient. Front Pharmacol. 2016;7:325. doi:10.3389/fphar.2016.00325
   Web of Science ®Google Scholar
• Ye X, Huang A, Wang X, Wen C, Hu L, Lin G. Linezolid inhibited synthesis of ATP in mitochondria: based on GC-MS metabolomics and HPLC method. Biomed Res Int. 2018;2018:3128270. doi:10.1155/2018/3128270
   Web of Science ®Google Scholar
• Engvall M, Kawasaki A, Carelli V, et al. Case report: a novel mutation in the mitochondrial MT-ND5 gene is associated with Leber Hereditary Optic Neuropathy (LHON). Front Neurol. 2021;12:652590. doi:10.3389/fneur.2021.652590
   Web of Science ®Google Scholar
• Lee S, Kang BH, Ryu WY, Um SJ, Roh MS, Son C. Is severe and long-lasting linezolid-induced optic neuropathy reversible? Intern Med. 2018;57(24):3611–3613. doi:10.2169/internalmedicine.1344-18
   PubMed Web of Science ®Google Scholar